Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Roden

Showing results (141-150 of 175) with videos related to

Pageof 18
Sort By:
The American Journal of Surgical Pathology|January 31, 2025
Clinicopathologic Features and Viral Status of Low-risk HPV6 and HPV11-Associated Squamous Cell Carcinoma of the Uterine Cervix and VulvaGuy A Williams, Annie A Wu, Henrietta C Eugene, et al.
Vaccine|August 6, 2017
Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypesKirill Kalnin, Sudha Chivukula, Timothy Tibbitts, et al.
Plos One|June 14, 2023
Development and anticancer properties of Up284, a spirocyclic candidate ADRM1/RPN13 inhibitorRavi K Anchoori, Vidyasagar Anchoori, Brandon Lam, et al.
Virology|May 12, 2005
Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2Diana V Pastrana, Ratish Gambhira, Christopher B Buck, et al.
Plos One|July 5, 2012
Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidateKaren Nieto, Margit Weghofer, Peter Sehr, et al.
Journal of Virology|May 19, 2017
Spontaneous and Vaccine-Induced Clearance of Mus Musculus Papillomavirus 1 InfectionRosie T Jiang, Joshua W Wang, Shiwen Peng, et al.
Cancer Research|February 19, 2013
Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunityTae Heung Kang, Chih-Ping Mao, Sung Yong Lee, et al.
Journal of Medicinal Chemistry|December 29, 2010
α,β-Unsaturated carbonyl system of chalcone-based derivatives is responsible for broad inhibition of proteasomal activity and preferential killing of human papilloma virus (HPV) positive cervical cancer cellsMartina Bazzaro, Ravi K Anchoori, Mohana Krishna R Mudiam, et al.
Plos One|January 16, 2020
Structure-function analyses of candidate small molecule RPN13 inhibitors with antitumor propertiesRavi K Anchoori, Marietta Tan, Ssu-Hsueh Tseng, et al.
Vaccines|June 27, 2024
Vaccination with a Human Papillomavirus L2 Multimer Provides Broad Protection against 17 Human Papillomavirus Types in the Mouse Cervicovaginal Challenge ModelZhenwei Han, Shen Wang, Ting Mu, et al.
Pageof 18

Showing results (141-150 of 175) with videos related to

Sort By:
Pageof 18
The American Journal of Surgical Pathology|January 31, 2025
Clinicopathologic Features and Viral Status of Low-risk HPV6 and HPV11-Associated Squamous Cell Carcinoma of the Uterine Cervix and VulvaGuy A Williams, Annie A Wu, Henrietta C Eugene, et al.
Vaccine|August 6, 2017
Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypesKirill Kalnin, Sudha Chivukula, Timothy Tibbitts, et al.
Plos One|June 14, 2023
Development and anticancer properties of Up284, a spirocyclic candidate ADRM1/RPN13 inhibitorRavi K Anchoori, Vidyasagar Anchoori, Brandon Lam, et al.
Virology|May 12, 2005
Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2Diana V Pastrana, Ratish Gambhira, Christopher B Buck, et al.
Plos One|July 5, 2012
Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidateKaren Nieto, Margit Weghofer, Peter Sehr, et al.
Journal of Virology|May 19, 2017
Spontaneous and Vaccine-Induced Clearance of Mus Musculus Papillomavirus 1 InfectionRosie T Jiang, Joshua W Wang, Shiwen Peng, et al.
Cancer Research|February 19, 2013
Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunityTae Heung Kang, Chih-Ping Mao, Sung Yong Lee, et al.
Journal of Medicinal Chemistry|December 29, 2010
α,β-Unsaturated carbonyl system of chalcone-based derivatives is responsible for broad inhibition of proteasomal activity and preferential killing of human papilloma virus (HPV) positive cervical cancer cellsMartina Bazzaro, Ravi K Anchoori, Mohana Krishna R Mudiam, et al.
Plos One|January 16, 2020
Structure-function analyses of candidate small molecule RPN13 inhibitors with antitumor propertiesRavi K Anchoori, Marietta Tan, Ssu-Hsueh Tseng, et al.
Vaccines|June 27, 2024
Vaccination with a Human Papillomavirus L2 Multimer Provides Broad Protection against 17 Human Papillomavirus Types in the Mouse Cervicovaginal Challenge ModelZhenwei Han, Shen Wang, Ting Mu, et al.
Pageof 18